Business
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
WATERTOWN, Mass., September 26, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2190,"height":732,"url":"https://media.zenfs.com/en/business-wire.com/e8457d9f9e2976621aa97401ab3a0f48"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CWs4YZ5s.lAlmgX39JVvHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e8457d9f9e2976621aa97401ab3a0f48","width":960,"height":321},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/gM4lazHzNWytswJ5R2XZpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e8457d9f9e2976621aa97401ab3a0f48","width":1200,"height":401}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m. ET","length":83,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":83,"olType":false},{"type":"text","content":"WATERTOWN, Mass., September 26, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.","length":490,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Information","length":39,"tagName":"p"},{"type":"text","content":"The live webcast can be accessed at "Events & Presentations" in the investors section of Enanta’s website. To participate by phone, please register for the call here. It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta’s website for approximately 30 days following the event.","length":477,"tagName":"p"},{"type":"text","content":"About Enanta Pharmaceuticals, Inc.","length":34,"tagName":"p"},{"type":"text","content":"Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the dis...